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 Diuretics are among the most frequently used drugs to treat hypertension, 
congestive heart failure, edema, and play a role in the prevention of some forms of 
recurrent nephrolithiasis 1-3. Most commonly used diuretics act by directly inhibiting 
tubular transport processes such as the loop diuretics blocking the Na+/K+/2Cl- -
cotransporter NKCC2 in the thick ascending limb of the loop of Henle, the thiazides 
and chlortalidones inhibiting the Na+/Cl- -cotransporter NCC in the distal convoluted 
tubule, or the potassium-sparing diuretics of the amiloride or triamterene type 
blocking the epithelial sodium channel ENaC in the connecting tubule and collecting 
duct. Other classes of diuretics interfere with metabolic or endocrine mechanisms 
linked to tubular transport processes such as in the case of the rather infrequently 
used carbonic anhydrase inhibitors (e.g. acetazolamide) that mostly reduce Na+/H+ 
exchanger activity, and the more widely used mineralocorticoid receptor blockers 
(e.g. spironolactone, eplerenone) reducing the stimulatory effect of aldosterone on 
ENaC mediated salt absorption. Two novel classes of substances increase diuresis 
but do not act primarily on salt reabsorptive pathways: the aquaretics blocking the V2 
vasopressin receptor reducing AQP2 activation by the antidiuretic hormone (e.g. 
tolvaptan) and the inhibitors of the SGLT2 Na+/glucose transporter (e.g. canagliflozin, 
dapagliflozin, and empagliflozin) primarily reducing proximal tubular glucose 
absorption causing osmotic diuresis 4-5.  
 The use of diuretics from the first group directly blocking salt reabsorption can 
be limited by hypo- or hyperkalemia or hypercalcemia. In CKD patients with 
increasingly lower GFR, the efficacy of drugs can be reduced requiring escalating 
doses or alternative drugs. The indication for SGLT2 inhibitors and vasopressin 
receptor antagonists are distinct and currently mostly restricted to the treatment of 
type 2 diabetes, ADPKD, or hyponatremic syndromes, respectively. Moreover, the 
efficacy of diurectics blocking salt absorptive pathways is often limited by the 
plasticity of the renal tubule and its ability to stimulate the growth and activity of 
downstream segments contributing to treatment-resistant hypertension 3, 6. Then 
combinations of diuretics acting in subsequent segments and on distinct pathways 
may help to improve diuretic efficacy.  
 The collecting duct is the last site of salt reabsorption and contributes to up to 
2 % of absorption of the filtered salt load. Renal salt reabsorption in the collecting 
duct depends on several factors and transport pathways. Distal delivery of sodium 
and chloride is determined by glomerular filtration rate and the rate of reabsorption of 
both ions in upstream nephron segments. Particularly, NaCl reabsorption by the thick 
ascending limb of the loop of Henle and by the distal convoluted tubule influences the 
delivery of sodium and chloride to the collecting duct. There, sodium is reabsorbed in 
part by the epithelial Na+-channel ENaC which is stimulated by angiotensin II and 
aldosterone. Chloride absorption occurs via different routes, in part through the 
paracellular pathway requiring claudins 4 and 8 and through intercalated cells 7-8. In 
non-type A intercalated cells chloride can be directly reabsorbed in exchange for 
bicarbonate, a process mediated by the anion exchanger pendrin, or chloride 
absorption can be coupled to sodium absorption involving a more complex scheme. 
Secretion of 2 bicarbonate and absorption of 2 chloride ions by pendrin is driving the 
activity of another transporter, NDBCE (Na+-dependent bicarbonate-chloride 
exchanger), exchanging one intracellular chloride for one extracellular bicarbonate 
plus one sodium (figure 1). This results in the net absorption of NaCl 8.  
 Insights into the relevance of pendrin in renal salt handling come from human 
genetics studying patients with the rare Pendred syndrome and from various mouse 
models. Patients with Pendred syndrome due to mutations in pendrin (SLC26A6) 
suffer most notably from sensorineural deafness and frequently develop 
hypothyroidism and goiter. However, their renal phenotype has been studied very 
little to date. Hypochloremic alkalosis was reported in two cases with Pendred 
syndrome; however, the condition occurred only during acute illness or therapy with 
thiazides primarily causing volume depletion 9-10. Next to these incidental reports, 
detailed studies in mice suggest an important role of pendrin in renal control of salt 
excretion and blood pressure. Salt depletion or aldosterone stimulate pendrin 
expression and activity in parallel to other chloride and sodium transport proteins 
such as NaCl cotransporter NCC or the epithelial sodium channel ENaC 8. Mice 
lacking pendrin loose more salt during salt depletion and have lower blood pressure 
suggesting that pendrin is required for the renal capacity to conserve salt and 
maintain blood pressure. Moreover, pendrin deficient mice are partly protected from 
developing hypertension during high salt/ aldosterone treatment. Vice versa, mice 
overexpressing pendrin develop chloride sensitive hypertension 11.  
 Since salt absorption by the collecting duct is influenced by salt delivery, the 
role of pendrin in compensating for reduced salt absorption by earlier segments has 
been studied. On the one hand, chronic inhibition of NCC activity with thiazides 
increases pendrin expression whereas on the other hand concomitant genetic 
ablation of NCC and pendrin causes a severe syndrome of renal salt loss and volume 
depletion 8, 12. Similarly, deletion of NCC and the NDBCE transporter working in 
conjunction with pendrin leads also to salt wasting 13. Taken together, the biology of 
pendrin and its interactions with other salt transporting pathways make pendrin an 
attractive target for novel inhibitors that may be useful as diuretics standing alone or 
used in combination with existing drugs to enhance their efficacy. 
 Alan Verkman and colleagues identified novel compounds selectively inhibiting 
pendrin with  high affinity using a functional chemical library screen 14. As reported 
here in this issue of JASN, these compounds given to mice had per se no effect on 
diuresis or acid-base parameters in urine and blood. However, when given in 
combination with furosemide, pendrin inhibitors potentiated the diuretic effect of 
furosemide. Importantly, the pendrin inhibitor even further increased diuresis in mice 
given chronically furosemide. On the other hand, mice treated with 
hydrochlorothiazide plus pendrin inhibitor showed a paradoxical reduction in diuresis 
15. 
 Several issues are of major interest and some questions remain open. Next to 
tests of safety and pharmacokinetics in humans, the question remains whether 
pendrin inhibitor will have a similar diuretic potency in humans as in rodents. The 
relative number of pendrin expressing cells may be relatively lower in human kidney 
compared to rodent kidney and may thus limit its efficacy 16-17. 
 Next to kidney, pendrin (SLC26A4) is expressed in various other organs 
including thyroid glands, inner ear, adrenal glands, and airways which will impact on 
its side effects as well modulate its diuretic and anti-hypertensive effects. While 
pendrin function in inner ear and thyroid glands may be problematic and may cause 
side effects, the inhibition of adrenal gland pendrin may add to the beneficial effects 
of pendrin blockade in kidney. Pendrin function in adrenal glands appears to support 
aldosterone secretion and inhibition may help to reduce renal salt reabsorption as 
well as other extrarenal effects of aldosterone, e.g. in heart and vasculature 18. 
 Chronic treatment with loop diuretics as well as with thiazides and 
chlortalidones often cause hypokalemia due to the excessive stimulation of 
potassium secretion in the collecting duct by increased urinary flow and stimulation of 
ENaC activity which in turn increases ROMK mediated K+-secretion. The combination 
of the pendrin inhibitor with furosemide further increased urinary K+-excretion pointing 
to another possible side effect of this class of inhibitors. Also metabolic alkalosis was 
aggravated by the combination of furosemide and the pendrin inhibitor further 
underlining the potency of this combination.  
 The pendrin inhibitor reduced the diuretic response to thiazide treatment. At 
first glance this is surprising since the combined ablation of NCC and pendrin causes 
a massive diuresis and renal phenotype in mice 12. However, thiazides have also 
been reported to block not only NCC activity but also the NDCBE transporter working 
in conjunction with pendrin in the collecting duct. Thus, during acute treatment with 
thiazides, both NCC and NDCBE/pendrin dependent salt absorption may be blocked 
and further blockade with a pendrin inhibitor does not cause more salt wasting. In 
contrast, pendrin inhibition in adrenal glands may reduce filtration and thereby cause 
a paradoxical reduction in diuresis. Clearly, these effects will require more 
clarification and may also provide novel insights into the renal handling of chloride 
and the role of pendrin. 
 Pendrin inhibitors, if making the difficult way into clinics, may represent 
another promising new class of drugs targeting a tubular transport pathway like the 
more recently developed inhibitors of urea transporters or the renal ROMK potassium 
channel 19-20. Their specific application may be in the combination with other diuretics 
such as loop diuretics to address some of the adaptive responses of the tubular 
transport machinery contributing to the resistance to diuretics.  
 
Figure legend 
Figure 1: Transport pathways involved in salt absorption by the distal 
convoluted tubule and collecting system as targets of diuretics 
Scheme of a nephron depicting the major transport pathways targeted by commonly 
used diuretics: In the thick ascending limb of the loop of Henle (TAL), furosemide and 
chlortalidon inhibit the NKCC2 cotransporter and in the distal convoluted tubule 
(DCT) thiazides block the NCC cotransporter. In the collecting system (first cells 
starting in the late DCT) potassium-sparing diuretics inhibit ENaC activity in principal 
cells (PC). Chloride absorption occurs in part through a pendrin-dependent process 
located in type B intercalated cells (B-IC) (basolateral V-ATPase) and non-type 
A/non-type B intercalated cells (non-A/non-B IC)(apical V-ATPase). V-ATPase driven 
proton secretion energizes chloride/bicarbonate exchange by pendrin. Coupling of 
pendrin activity to the Na+-dependent chloride/bicarbonate exchanger NDCBE allows 
for NaCl absorption. NDBCE may also be targeted by thiazides whereas pendrin can 
be blocked by novel inhibitors. 
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